Engineered Immune Cells in Cancer Immunotherapy: from Discovery to “Off-the-Shelf” Development
Date: February 15, 2019
Translating the potency of the anti-cancer immune system into overall survival
Sidra Medicine is proud to host Qatar’s first International Workshop on Engineered Immune Cells in Cancer Immunotherapy (EICCI). The workshop will take place on the 15th and 16th of February 2019 at Sidra Medicine in Doha, Qatar.
This workshop will represent an unparalleled opportunity for learning, fostering innovative scientific and clinical programs and for networking for the development of novel effective therapeutic interventions for cancer patients. EICCI will represent the unique opportunity to stay at the forefront of this rapidly evolving field and to become part of the academic and industry community dedicated to the development of anti-cancer engineered immune cells.
EICCI will bring together worldwide experts in immunology, oncology, hematology, gene and cell therapy while unveiling breakthrough technologies to implement the efficacy and manufacturing of cell therapies. It will also contribute to achieve the unmet need of providing innovative and highly efficacious treatments to patients affected with advanced neoplastic diseases in Qatar and in the MENA region.
This Workshop has been organized based on the joint interest and commitment of Sidra Medicine and National Center for Cancer Care and Research (NCCCR), Hamad Medical Corporation to be able to provide engineered T cell therapies for both pediatric and adult cancer patients in Qatar.
This event has been built with the partnership of the non-profit humanitarian charity Qatar Cancer Society.
Join us for this exciting event.
Registration & Abstract submission
Abstract submission deadline: 27th January 2019
The preworkshop Symposium is an Accredited Group Learning Activity (Category 1) as defined by the Qatar Council for Healthcare Practitioners – Accreditation Department and is approved for a maximum of 3.25
